Top

Published in:

01-06-2009 | NON-THEMATIC REVIEW

Emerging role of nuclear protein 1 (NUPR1) in cancer biology

Authors: Uttio Roy Chowdhury, Rajeev S. Samant, Oystein Fodstad, Lalita A. Shevde

Published in: Cancer and Metastasis Reviews | Issue 1-2/2009

Abstract

NUPR1, or p8 or com1, was first identified from rat pancreas during acute pancreatitis and later as a gene whose expression was upregulated in metastatic breast cancer cells. NUPR1 is a molecule whose expression is upregulated in response to stress and is hence influenced by the host microenvironment. While NUPR1 has been implicated in several diseases, there is no singular biochemical pathway that can be attributed to its role in cancer. NUPR1 has been found to aid the establishment of metastasis and to play a key role in the progression of several malignancies including those of breast, thyroid, brain and pancreas. NUPR1 has been implicated in inducing chemoresistance in pancreatic and breast cancer cells, protecting them from apoptosis and making tumor cells genetically unstable. In prostate cancer, however, NUPR1 appears to have tumor suppressive activity. Understanding the mechanism of action of the multifaceted functions of NUPR1 may open up new dimensions towards creating novel therapies against cancer as well as other pathologies. This review draws on several published studies on NUPR1, mainly in cancer biology, and assesses NUPR1 from the perspective of its functional role in making cancer cells resistant to the action of conventional chemotherapeutic drugs.

Mallo, G. V., Fiedler, F., Calvo, E. L., Ortiz, E. M., Vasseur, S., Keim, V., et al. (1997). Cloning and expression of the rat p8 cDNA, a new gene activated in pancreas during the acute phase of pancreatitis, pancreatic development, and regeneration, and which promotes cellular growth. Journal of biological chemistry, 272, 32360–32369.PubMedCrossRef

Ree, A. H., Tvermyr, M., Engebraaten, O., Rooman, M., Rosok, O., Hovig, E., et al. (1999). Expression of a novel factor in human breast cancer cells with metastatic potential. Cancer research, 59, 4675–4680.PubMed

Giroux, V., Malicet, C., Barthet, M., Gironella, M., Archange, C., Dagorn, J. C., et al. (2006). p8 is a new target of gemcitabine in pancreatic cancer cells. Clinical cancer research, 12, 235–241.PubMedCrossRef

Clark, D. W., Mitra, A., Fillmore, R. A., Jiang, W. G., Samant, R. S., Fodstad, O., et al. (2008). NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stress. Current cancer drug targets, 8(5), 421–430.PubMedCrossRef

Vasseur, S., Vidal Mallo, G., Fiedler, F., Bodeker, H., Canepa, E., Moreno, S., et al. (1999). Cloning and expression of the human p8, a nuclear protein with mitogenic activity. European journal of biochemistry, 259, 670–675.PubMedCrossRef

Vasseur, S., Hoffmeister, A., Garcia-Montero, A., Barthet, M., Saint-Michel, L., Berthezene, P., et al. (2003). Mice with targeted disruption of p8 gene show increased sensitivity to lipopolysaccharide and DNA microarray analysis of livers reveals an aberrant gene expression response. BMC Gastroenterol, 3, 25.PubMedCrossRef

Taieb, D., Malicet, C., Garcia, S., Rocchi, P., Arnaud, C., Dagorn, J. C., et al. (2005). Inactivation of stress protein p8 increases murine carbon tetrachloride hepatotoxicity via preserved CYP2E1 activity. Hepatology, 42, 176–182.PubMedCrossRef

Vasseur, S., Hoffmeister, A., Garcia-Montero, A., Mallo, G. V., Feil, R., Kuhbandner, S., et al. (2002). p8-deficient fibroblasts grow more rapidly and are more resistant to adriamycin-induced apoptosis. Oncogene, 21, 1685–1694.PubMedCrossRef

Courjal, F., & Theillet, C. (1997). Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. Cancer research, 57, 4368–4377.PubMed

10.

Valacco, M. P., Varone, C., Malicet, C., Canepa, E., Iovanna, J. L., Moreno, S. (2006). Cell growth-dependent subcellular localization of p8. Journal of cellular biochemistry, 97, 1066–1079.PubMedCrossRef

11.

Malicet, C., Lesavre, N., Vasseur, S., & Iovanna, J. L. (2003). p8 inhibits the growth of human pancreatic cancer cells and its expression is induced through pathways involved in growth inhibition and repressed by factors promoting cell growth. Molecular cancer, 2, 37.PubMedCrossRef

12.

Dingwall, C., & Laskey, R. A. (1991). Nuclear targeting sequences—a consensus? Trends in biochemical sciences, 16, 478–481.PubMedCrossRef

13.

Goruppi, S., & Kyriakis, J. M. (2004). The pro-hypertrophic basic helix-loop-helix protein p8 is degraded by the ubiquitin/proteasome system in a protein kinase B/Akt— and glycogen synthase kinase-3-dependent manner, whereas endothelin induction of p8 mRNA and renal mesangial cell hypertrophy require NFAT4. Journal of biological chemistry, 279, 20950–20958.PubMedCrossRef

14.

Path, G., Opel, A., Knoll, A., & Seufert, J. (2004). Nuclear protein p8 is associated with glucose-induced pancreatic beta-cell growth. Diabetes, 53(Suppl 1), S82–85.PubMedCrossRef

15.

Vasseur, S., Folch-Puy, E., Hlouschek, V., Garcia, S., Fiedler, F., Lerch, M. M., et al. (2004). p8 improves pancreatic response to acute pancreatitis by enhancing the expression of the anti-inflammatory protein pancreatitis-associated protein I. Journal of biological chemistry, 279, 7199–7207.PubMedCrossRef

16.

Carracedo, A., Egia, A., Guzman, M., & Velasco, G. (2006). p8 Upregulation sensitizes astrocytes to oxidative stress. FEBS letters, 580, 1571–1575.PubMedCrossRef

17.

Goruppi, S., Patten, R. D., Force, T., & Kyriakis, J. M. (2007). Helix-loop-helix protein p8, a transcriptional regulator required for cardiomyocyte hypertrophy and cardiac fibroblast matrix metalloprotease induction. Molecular and cellular biology, 27, 993–1006.PubMedCrossRef

18.

Malicet, C., Giroux, V., Vasseur, S., Dagorn, J. C., Neira, J. L., & Iovanna, J. L. (2006). Regulation of apoptosis by the p8/prothymosin alpha complex. Proceedings of the National Academy of Sciences of the United States of America, 103, 2671–2676.PubMedCrossRef

19.

Ree, A. H., Pacheco, M. M., Tvermyr, M., Fodstad, O., & Brentani, M. M. (2000). Expression of a novel factor, com1, in early tumor progression of breast cancer. Clinical cancer research, 6, 1778–1783.PubMed

20.

Su, S. B., Motoo, Y., Iovanna, J. L., Berthezene, P., Xie, M. J., Mouri, H., et al. (2001). Overexpression of p8 is inversely correlated with apoptosis in pancreatic cancer. Clinical cancer research, 7, 1320–1324.PubMed

21.

Su, S. B., Motoo, Y., Iovanna, J. L., Xie, M. J., Mouri, H., Ohtsubo, K., et al. (2001). Expression of p8 in human pancreatic cancer. Clinical cancer research, 7, 309–313.PubMed

22.

Quirk, C. C., Seachrist, D. D., & Nilson, J. H. (2003). Embryonic expression of the luteinizing hormone beta gene appears to be coupled to the transient appearance of p8, a high mobility group-related transcription factor. Journal of biological chemistry, 278, 1680–1685.PubMedCrossRef

23.

Mohammad, H. P., Seachrist, D. D., Quirk, C. C., & Nilson, J. H. (2004). Reexpression of p8 contributes to tumorigenic properties of pituitary cells and appears in a subset of prolactinomas in transgenic mice that hypersecrete luteinizing hormone. Molecular endocrinology, 18, 2583–2593.PubMedCrossRef

24.

Brannon, K. M., Million Passe, C. M., White, C. R., Bade, N. A., King, M. W., & Quirk, C. C. (2007). Expression of the high mobility group A family member p8 is essential to maintaining tumorigenic potential by promoting cell cycle dysregulation in LbetaT2 cells. Cancer letter, 254, 146–155.CrossRef

25.

Ito, Y., Yoshida, H., Motoo, Y., Miyoshi, E., Iovanna, J. L., Tomoda, C., et al. (2003). Expression and cellular localization of p8 protein in thyroid neoplasms. Cancer letter, 201, 237–244.CrossRef

26.

Ree, A. H., Bratland, A., Kroes, R. A., Aasheim, H. C., Florenes, V. A., Moskal, J. R., et al. (2002). Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases. Anticancer research, 22, 1949–1957.PubMed

27.

Bratland, A., Risberg, K., Maelandsmo, G. M., Gutzkow, K. B., Olsen, O. E., Moghaddam, A., et al. (2000). Expression of a novel factor, com1, is regulated by 1,25-dihydroxyvitamin D3 in breast cancer cells. Cancer research, 60, 5578–5583.PubMed

28.

Vasseur, S., Hoffmeister, A., Garcia, S., Bagnis, C., Dagorn, J. C., & Iovanna, J. L. (2002). p8 is critical for tumour development induced by rasV12 mutated protein and E1A oncogene. EMBO reports, 3, 165–170.PubMedCrossRef

29.

Blazquez, C., Salazar, M., Carracedo, A., Lorente, M., Egia, A., Gonzalez-Feria, L., et al. (2008). Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer research, 68, 1945–1952.PubMedCrossRef

30.

Blazquez, C., Carracedo, A., Salazar, M., Lorente, M., Egia, A., Gonzalez-Feria, L., et al. (2008). Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity? Neuropharmacology, 54, 235–243.PubMedCrossRef

31.

Carracedo, A., Gironella, M., Lorente, M., Garcia, S., Guzman, M., Velasco, G., et al. (2006). Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer research, 66, 6748–6755.PubMedCrossRef

32.

Jiang, W. G., Watkins, G., Douglas-Jones, A., Mokbel, K., Mansel, R. E., & Fodstad, O. (2005). Expression of Com-1/P8 in human breast cancer and its relevance to clinical outcome and ER status. International journal of cancer, 117, 730–737.CrossRef

33.

Jiang, W. G., Davies, G., & Fodstad, O. (2005). Com-1/P8 in oestrogen regulated growth of breast cancer cells, the ER-beta connection. Biochemical and biophysical research communications, 330, 253–262.PubMedCrossRef

34.

Jiang, W. G., Davies, G., Martin, T. A., Kynaston, H., Mason, M. D., & Fodstad, O. (2006). Com-1/p8 acts as a putative tumour suppressor in prostate cancer. International Journal of Molecular Medicine, 18, 981–986.PubMed

35.

Ishida, M., Miyamoto, M., Naitoh, S., Tatsuda, D., Hasegawa, T., Nemoto, T., et al. (2007). The SYT-SSX fusion protein down-regulates the cell proliferation regulator COM1 in t(x;18) synovial sarcoma. Molecular and cellular biology, 27, 1348–1355.PubMedCrossRef

36.

Dulic, V., Stein, G. H., Far, D. F., & Reed, S. I. (1998). Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition. Molecular and cellular biology, 18, 546–557.PubMed

37.

Medema, R. H., Klompmaker, R., Smits, V. A., & Rijksen, G. (1998). p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene, 16, 431–441.PubMedCrossRef

38.

Niculescu 3rd, A. B., Chen, X., Smeets, M., Hengst, L., Prives, C., & Reed, S. I. (1998). Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Molecular and cellular biology, 18, 629–643.PubMed

39.

Smits, V. A., & Medema, R. H. (2001). Checking out the G(2)/M transition. Biochimica et biophysica acta, 1519, 1–12.PubMed

40.

Staversky, R. J., Vitiello, P. F., Gehen, S. C., Helt, C. E., Rahman, A., Keng, P. C., et al. (2006). p21(Cip1/Waf1/Sdi1) protects against hyperoxia by maintaining expression of Bcl-X(L). Free radical biology & medicine, 41, 601–609.CrossRef

41.

Tian, H., Wittmack, E. K., & Jorgensen, T. J. (2000). p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer research, 60, 679–684.PubMed

42.

Zhang, Y., Fujita, N., & Tsuruo, T. (1999). Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene, 18, 1131–1138.PubMedCrossRef

43.

Vitiello, P. F., Staversky, R. J., Gehen, S. C., Johnston, C. J., Finkelstein, J. N., Wright, T. W., et al. (2006). p21Cip1 protection against hyperoxia requires Bcl-XL and is uncoupled from its ability to suppress growth. American journal of pathology, 168, 1838–1847.PubMedCrossRef

44.

Wang, Z., Goulet 3rd, R., Stanton, K. J., Sadaria, M., & Nakshatri, H. (2005). Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. Anticancer research, 25, 2367–2379.PubMed

45.

Shoemaker, A. R., Oleksijew, A., Bauch, J., Belli, B. A., Borre, T., Bruncko, M., et al. (2006). A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer research, 66, 8731–8739.PubMedCrossRef

46.

Trump, D. L., Muindi, J., Fakih, M., Yu, W. D., & Johnson, C. S. (2006). Vitamin D compounds: clinical development as cancer therapy and prevention agents. Anticancer research, 26, 2551–2556.PubMed

47.

Garcia-Montero, A. C., Vasseur, S., Giono, L. E., Canepa, E., Moreno, S., Dagorn, J. C., et al. (2001). Transforming growth factor beta-1 enhances Smad transcriptional activity through activation of p8 gene expression. Biochemical journal, 357, 249–253.PubMedCrossRef

48.

Massague, J. (1998). TGF-beta signal transduction. Annual Reviews of Biochemical, 67, 753–791.CrossRef

49.

Chen, Y. G., Hata, A., Lo, R. S., Wotton, D., Shi, Y., Pavletich, N., et al. (1998). Determinants of specificity in TGF-beta signal transduction. Genes & development, 12, 2144–2152.CrossRef

50.

Kretzschmar, M., & Massague, J. (1998). SMADs: mediators and regulators of TGF-beta signaling. Current opinion in genetics & development, 8, 103–111.CrossRef

51.

Hoffmeister, A., Ropolo, A., Vasseur, S., Mallo, G. V., Bodeker, H., Ritz-Laser, B., et al. (2002). The HMG-I/Y-related protein p8 binds to p300 and Pax2 trans-activation domain-interacting protein to regulate the trans-activation activity of the Pax2A and Pax2B transcription factors on the glucagon gene promoter. Journal of biological chemistry, 277, 22314–22319.PubMedCrossRef

52.

Carracedo, A., Lorente, M., Egia, A., Blazquez, C., Garcia, S., Giroux, V., et al. (2006). The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell, 9, 301–312.PubMedCrossRef

53.

Gort, E. H., van Haaften, G., Verlaan, I., Groot, A. J., Plasterk, R. H., Shvarts, A., et al. (2008). The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2alpha. Oncogene, 27, 1501–1510.PubMedCrossRef

54.

Gort, E. H., Groot, A. J., van der Wall, E., van Diest, P. J., & Vooijs, M. A. (2008). Hypoxic regulation of metastasis via hypoxia-inducible factors. Current molecular medicine, 8, 60–67.PubMedCrossRef

55.

Bristow, R. G., & Hill, R. P. (2008). Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nature reviews. Cancer, 8, 180–192.PubMedCrossRef

56.

Bindra, R. S., Schaffer, P. J., Meng, A., Woo, J., Maseide, K., Roth, M. E., et al. (2005). Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability. Annals of the New York Academy of Sciences, 1059, 184–195.PubMedCrossRef

57.

Rankin, E. B., & Giaccia, A. J. (2008). The role of hypoxia-inducible factors in tumorigenesis. Cell death and differentiation, 15, 678–685.PubMedCrossRef

58.

Mehlen, P., & Puisieux, A. (2006). Metastasis: a question of life or death. Nature reviews. Cancer, 6, 449–458.PubMedCrossRef

Title: Emerging role of nuclear protein 1 (NUPR1) in cancer biology
Authors: Uttio Roy Chowdhury
Rajeev S. Samant
Oystein Fodstad
Lalita A. Shevde
Publication date: 01-06-2009
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 1-2/2009
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-009-9183-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-2/2009

Preface

Tissue architecture and function: dynamic reciprocity via extra- and intra-cellular matrices

Tumor stroma derived biomarkers in cancer

Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility

Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion

EMT, the cytoskeleton, and cancer cell invasion

Keynote webinar | Spotlight on antibody–drug conjugates in cancer